IFP Advisors Inc grew its position in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 39.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 49,988 shares of the financial services provider’s stock after purchasing an additional 14,115 shares during the quarter. IFP Advisors Inc’s holdings in iShares Biotechnology ETF were worth $9,507,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Citigroup Inc. boosted its holdings in shares of iShares Biotechnology ETF by 40.9% during the 4th quarter. Citigroup Inc. now owns 5,242,688 shares of the financial services provider’s stock worth $884,808,000 after buying an additional 1,521,992 shares during the period. Raymond James Financial Inc. raised its holdings in iShares Biotechnology ETF by 286.2% in the 4th quarter. Raymond James Financial Inc. now owns 994,311 shares of the financial services provider’s stock worth $167,810,000 after acquiring an additional 736,881 shares during the period. Bank of America Corp DE lifted its position in iShares Biotechnology ETF by 10.8% during the 1st quarter. Bank of America Corp DE now owns 7,259,501 shares of the financial services provider’s stock worth $1,225,767,000 after acquiring an additional 707,343 shares during the last quarter. LPL Financial LLC boosted its holdings in iShares Biotechnology ETF by 145.9% during the fourth quarter. LPL Financial LLC now owns 992,799 shares of the financial services provider’s stock valued at $167,555,000 after acquiring an additional 589,033 shares during the period. Finally, Janney Montgomery Scott LLC boosted its holdings in iShares Biotechnology ETF by 1,871.5% during the fourth quarter. Janney Montgomery Scott LLC now owns 619,550 shares of the financial services provider’s stock valued at $104,562,000 after acquiring an additional 588,124 shares during the period. 62.45% of the stock is currently owned by institutional investors and hedge funds.
iShares Biotechnology ETF Stock Down 0.9%
Shares of NASDAQ:IBB opened at $205.49 on Thursday. The stock’s 50-day moving average is $199.14 and its 200-day moving average is $181.02. iShares Biotechnology ETF has a 52-week low of $138.79 and a 52-week high of $217.12.
iShares Biotechnology ETF Cuts Dividend
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Stories
- Five stocks we like better than iShares Biotechnology ETF
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
- GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus
- Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer
- Sovereign AI: Palantir and Nebius Cut the Cloud Cord
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
